COVID-19 pandemic, an unprecedented devastation, humanity needs an urgent cure to save the mankind from this deadly disease. Over six million people have been infected worldwide, with 6.3% reported deaths till date. SARS-CoV-2 virus, responsible for Novel Coronavirus (COVID-19) disease has been isolated recently and the vaccine's development is at nascent stage. At present, there are a few anecdotal evidences that anti-viral/anti-in ammatory/anti-malarial drugs can mitigate the disease. In the present study, we envision the potency of traditional Indian medicinal compounds that can be used as an effective drug. The viral SARS Coronavirus E protein plays a key role in virus life cycle and can be a potential drug target for the development of anti-SARS-CoV-2 drugs. Using the crystal structure of the CoVE protein, we performed virtual PyRX screening of Indian medicinal compounds which are reported to have e cacy in the treatment of some viral infections. Molecular docking studies were evaluated based on scores analysed by CavityPlus. The herbal compounds used were found to be more e cient in inhibiting the virus as compared to commercially available drugs. The results showed that β-boswellic acid and Glycyrrhizic acid possessed the best binding as a ligand with target molecule having binding a nity of-9.1 kcal/mol amongst eleven compounds screened. The study demonstrated that these are found to be strong SARS-CoV-2E protein inhibitors as they revealed compatible, near perfect dock in the overlapping region of functional viral protein pockets. These potential hit compounds can pave a way for designing of anti-viral therapeutics.

With more than 1,800,000 cases and 110,000 deaths globally, COVID-19 is one of worst infectious disease outbreaks in history. This paper provides a critical review of the available evidence regarding the lessons learned from the Chinese experience with COVID-19 prevention and management. The steps that have led to a near disappearance of new cases in China included rapid sequencing of the virus to establish testing kits, which allowed tracking of infected persons in and out of Wuhan. In addition, aggressive quarantine measures included the R ESUM EAvec plus de 1 800 000 cas et 110 000 d ecès dans le monde, la COVID-19 est l'une des pires eclosions de maladies infectieuses de l'histoire. Ce document pr esente un examen critique des constats disponibles concernant les leçons tir ees de l'exp erience chinoise en matière de pr evention et de gestion de la COVID-19. Les mesures qui ont conduit à la quasi-disparition des nouveaux cas en Chine comprenaient le s equençage rapide du virus pour etablir des trousses de tests, ce qui a permis de suivre les personnes infect ees à l'int erieur et à Since mid-December 2019, there has been a worldwide outbreak of coronavirus disease (COVID)e19, caused by SARS-CoV-2 (formerly 2019-nCoV or HCoV-19) and first detected in Wuhan, China. The incubation period is 1-14 days (mean 5-6 days) in most cases, but can be as long as 24 days. 1 The most commonly seen characteristics of COVID-19 are fever, cough, and abnormal chest computed tomography. 2,3 At present, the Chinese chrysanthemum bat is thought to be the origin of SARS-CoV-2, based on sequence homology of 96% between SARS-CoV-2 and Bat-CoV-RaTG13. 4,5 The pangolin has been proposed as an intermediate host, but this has not been confirmed. 6,7 Human-to-human transmission of SARS-CoV-2 occurs mainly via respiratory droplets, 1 direct contact, 1 asymptomatic transmission, 8,9 and intrafamilial transmission. 3 SARS-CoV-2 can affect any demographic, including senior citizens, children, and pregnant women. 3,10 According to the World Health Organisation (WHO),

No abstract

pensated advanced chronic liver disease (cACLD) of different etiologies (1). The authors developed simple classification rules to detect CSPH, validated ANTCI-PATE study models for predicting CSPH in cohorts of hepatitis C virus (HCV) and alcoholic liver disease. In addition, a normogram based on liver stiffness measurement (LSM), platelet counts, and body mass index predicted CSPH in patients with nonalcoholic steatohepatitis with good accuracy. The results are important as detection and treatment of CSPH with beta-blockers improve survival. We would like to highlight a few important points pertaining to the findings of this study.With most patients recruited retrospectively, there is a possibility of selection bias. As such, prevalence of portal hypertension and CSPH may have been overestimated. Although CSPH usually exists in patients above an LSM of 10 kPa, mild portal hypertension can be present in patients with lower LSM (which were excluded from the study). Hence, it is difficult to give accurate estimates of true prevalence in view of nonconsecutive recruitment.In the absence of validation cohorts, the results of LSM indices derived to diagnose/exclude CSPH are difficult to generalize. The authors derived and then tested the best discriminative values of LSM to rule in/out CSPH in the etiological subgroups of same cohort. Similarly, accuracy of assessing CSPH at different point of time is important in patients with HCV with advent of direct acting antivirals (DAA). CSPH reverses in about 40% of patients treated with DAA; hence, its assessment is more relevant in patients after treatment (2). The utility of ANTI-CPATE model (derived in pre-DAA era) needs confirmation in patients who have received DAA.An important issue detecting CSPH with noninvasive models is the target population on which they should be applied. Detecting CSPH in patients with cACLD without varices on endoscopy should be the focus as this is the subset for whom diagnosis is possible only on hemodynamic studies. Such patients have lower LSM and a lower prevalence of CSPH than those with varices (3). Constructing models for detecting CSPH may be more relevant in this subgroup of cACLD than deriving them in entire cohort as prevalence of CSPH is an important determinant of performance of indices detecting it.